Background--Small artery pathophysiology is frequently invoked as a cause of obesity-related diastolic heart failure. However, evidence to support this hypothesis is scant, particularly in humans.
H eart failure describes a clinical spectrum with a number of different etiologies. Traditionally, although the clinical focus has been on heart failure associated with reduced left ventricular ejection fraction, a second category of heart failure is recognized, in which systolic function is preserved but symptoms and complications still occur. The natural history of heart failure with preserved ejection fraction (HFpEF) describes a preclinical phase, in which there is diastolic dysfunction in the absence of symptoms. 1 Imaging studies with echocardiography at this early stage of disease (Grade I or Ia) reveal characteristic patterns of impaired diastolic relaxation, with or without mild evidence of increased filling pressures. The reduction in left ventricular (LV) compliance leading to diastolic dysfunction causes progressive change in atrial morphology and function that represent early surrogate markers for HFpEF. Although our understanding of the causes of HFpEF is some years behind heart failure with reduced ejection fraction, epidemiological studies have shown that there are disproportionately high rates of diabetes mellitus, hypertension, and obesity in these patients. 2, 3 This has become an area of intense interest, and a number of conceptual models have been proposed to explain the connection between these risk factors and the development of symptomatic heart failure. 4 One such model is that microvascular disease underpins changes to the myocardium seen in HFpEF, through inflammatory and redox pathways. 5 When considering the profound effect that these same cardiovascular 6 and metabolic risk 7 factors have on small artery structure and function, 8 and consequently the prognostic relevance of these changes to target organ damage, 9 positioning resistance vessels at the center of any mechanistic framework in HFpEF seems justified. However, there are currently no studies that have explored the relationship between small resistance arteries and the heart in the setting of human obesity. In contrast to the paucity of small artery studies, large artery-to-heart studies have yielded many valuable insights into the vascular origins of myocardial dysfunction, 10 correlating aortic pulse wave velocity with left atrial remodeling in hypertensive patients 11 or demonstrating an association between reductions in arterial compliance and progressively abnormal diastolic function in hypertensive patients with exertional dyspnea.
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Pathological small artery remodeling frequently precedes larger artery dysfunction and target organ damage. Furthermore, metabolic disease, especially diabetes mellitus and obesity, influences growth of the small artery wall in response to elevated blood pressures. 8, 13 Thus, we hypothesized that alterations in small artery wall-to-lumen ratio and arterial wall hypertrophy would correlate with left atrial remodeling and diastolic impairment in patients with metabolic syndrome. We investigated this by performing echocardiography in patients with obesity and metabolic syndrome and pairing this with small artery structural and functional profiling of subcutaneous small arteries.
Methods

Study Population
Seventeen participants with National Cholesterol Education Program Adult Treatment Panel III defined metabolic syndrome 14 and 5 control participants were recruited from a general medicine clinic and a day case programmed investigation unit at Manchester Royal Infirmary. All participants gave full written informed consent for the study, which was approved by the Local Research Ethics Committee. On the day of study, fasting venous blood samples were taken to assess renal function, glucose, and lipid profile in addition to the inflammatory markers: high-sensitivity Creactive protein,tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6). Blood pressure was measured with subjects sitting, after 15 minutes of rest, by a semiautomatic machine (OMRON 705 CP, White Medical) with a mean of 3 readings recorded. Anthropometric measurements were also taken. Apart from hypertension or abnormalities of lipid metabolism, patients were excluded if diagnosed with chronic disease (eg, diabetes mellitus, heart, renal, or inflammatory disease).
Definition of Metabolic Syndrome and Insulin Resistance
The 
synthase inhibitor, the responses to acetylcholine were repeated as in step 2 above.
Pressure Myography: Passive Structure Measurement
The vessel was superfused for 20 minutes with Ca-free PSS containing 2 mmol/L ethylene glycol-bis (-amino ethyl ether)-N,N,N 1 ,N 1 -tetraacetic acid to ensure the vessels were devoid of active tone. To determine the structural properties of the arteries, the intraluminal pressure was reduced to 3 mm Hg to determine the unstressed diameter and then increased in steps to 20, 40, 60, 80, 100, 120, 140, 160, and 180 mm Hg.
Calculations
The wall/lumen ratio was calculated as WT/D9100, where WT is wall thickness and D is lumen diameter. Wall cross-sectional area (CSA) was calculated as:
Echocardiography
Echocardiographic studies were performed by a single operator (ML) who was blinded to the patient status at the time of the scan. Standard parasternal and apical imaging planes were obtained with commercially available echocardiographic equipment (Sonos 5500; Philips Medical Systems, Andover, MA). Images were stored as digital loops to optical disc for later analysis. Cardiac chamber quantification was performed according to American Society of Echocardiography guidelines. 17 Left atrial volume was calculated using the modified Simpsons method in the 4-and 2-chamber apical views at endsystole. Transmitral pulsed wave Doppler was used to obtain early (E wave) and late (A wave) diastolic filling velocities and E/ A ratio as a marker of diastolic function. Myocardial performance index was calculated as has been described previously. 18 LV mass was calculated using the formula:
Tissue Doppler parameters were measured using pulsedwave tissue Doppler imaging with the sampling cursor positioned at the septal and lateral mitral valve annulus. Early (E 0 ) and late (A 0 ) myocardial diastolic velocities were measured and E/E 0 ratio was calculated as a marker of left atrial pressure.
Statistical Analysis
Data are expressed as meanAESD. Comparison of characteristics between groups were made using the MannWhitney U test. Data for all diastolic parameters (mean tissue Doppler imaging E:A, mean E:E 0 , mean E:A and 2-chamber left atrial volume were transformed using log base 10 to normalize skewed distributions. The independent variables for this study were therefore CSA, wall thickness, wall:lumen ratio, endothelial function, and highsensitivity C-reactive protein. Baseline characteristics and differences between control subjects (n=5) and patients with metabolic syndrome (n=17). Values are meanAESD. HDL indicates high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein).
Results
Patient Demographics
A comparison of the demographic data between the metabolic syndrome group and controls is given in Table 1 . Those with metabolic syndrome had significantly higher mean body mass index and leptin. The mean level of high-density lipoprotein cholesterol was significantly lower in the metabolic syndrome group, while there was no significant difference in the mean level of triglycerides between the 2 groups.
Echocardiography, Small Artery Structure and Function in Metabolic Syndrome
Endothelial function ( Figure 1A ) was measured as average maximal relaxation to acetylcholine. Those with metabolic syndrome had significantly impaired endothelial function compared with control participants (86.74AE11.60% versus 98.70AE4.31%, P=0.004). This level of damage is consistent with that seen in other clinical studies of small artery function in obesity. Endothelial function ranged from normal (99.2% of resting diameter after maximal acetylcholine concentrations) to significantly impaired (59.6% of resting diameter) in the metabolic syndrome group. Data were also collected on acetylcholine relaxations after 1-hour incubation with a NOS inhibitor (N G -monomethyl-L-arginine) and presented in the dose-response curve in Figure 1B . Of the small artery structural indices, mean wall thickness was significantly greater in patients with metabolic syndrome compared with control participants, consistent with previous studies. There were no significant differences in cross-sectional area and wall-to-lumen ratio of the small arteries between the 2 groups ( Table 2 ). There were no significant differences in left ventricular ejection fraction between the control group and patients 
Correlations Between Subcutaneous Small Artery Structure and Function and Cardiac Parameters in Patients With Metabolic Syndrome
As summarized in Table 3 and Figure 2 , following adjustment for age and sex, a statistically significant association was found between 2-chamber left atrial volume and both wall thickness (b=0.718, P=0.02) and wall-to-lumen ratio (b=0.605, P=0.02). In addition, wall-to-lumen ratio was also significantly associated with lateral E:E 0 values (b=0.596, P=0.02). A significant inverse relationship was observed between lateral E:E 0 and IL-6 (b=À0.868, P=0.03). In contrast, no significant associations were observed between cardiac parameters and endothelial function, before or after incubation with N G -monomethyl-L-arginine.
Discussion
We herein report the first study to correlate small artery structural and functional indices with target organ diastolic impairment in patients with metabolic syndrome. Our most important observation was that in patients with metabolic syndrome, abnormal growth of the small artery wall was closely associated with the degree of diastolic dysfunction. By contrast, there was no correlation between the degree of endothelial damage and diastolic dysfunction, even though there was substantial impairment to the vasodilatory capacity of the vascular endothelium in obese patients. As such, our results lend weight to the increasingly held view that abnormal small artery remodeling is relevant to the pathogenesis of downstream target organ damage in obesity and type 2 diabetes mellitus. 8, 19, 20 The microcirculation serves several critical functions, including autoregulation of hydrostatic pressures and control of local and systemic peripheral vascular resistance. 21, 22 We examined small arteries of between 100 and 150 lm in lumen diameter, which form an important component of the resistance vasculature. The small artery profile, specifically the integrity of the myogenic response and structural changes to the arterial wall, are both robust prognostic parameters for subsequent target organ damage. 9 Pathological alterations in subcutaneous small artery structure associate strongly with cardiovascular mortality, 19, 23 particularly outward growth of the small artery wall. 19 Obesity has a profound effect on both the structure and function of human subcutaneous small arteries: from a structural perspective, arteries exhibit an outward growth pattern with hypertrophy of the wall. 24, 25 Inclusion of a small "control group" in our study served to indicate the small artery phenotype of the cohort with metabolic syndrome. This confirmed greater wall thickness in obese individuals. Other groups have described more pronounced hypertrophic changes in obesity 26 and metabolic syndrome, 25 with increased wall-to-lumen ratio and crosssectional areas when compared with lean individuals. Detailed assessment of structural changes in metabolic syndrome versus health was not an aim of the current study, but previous investigations from our group and others have demonstrated that a number of metabolic factors contribute to wall hypertrophy 24 and that this is a dynamic process that is reversible with effective metabolic and blood pressure improvements. 8, 24 Structural changes of the arterial wall therefore represent a spectrum of progressive change, which are influenced by both lifestyle and drug therapy. Given the heterogeneous nature of metabolic syndrome, there will naturally be pathophysiological variations between different cohorts, and we have therefore provided detailed characterization of our study group in the patient demographics. Functionally, our ex vivo findings demonstrated reductions in acetylcholine-induced vasodilation and thickening of the small artery wall in the obese patients. Echocardiography in obese participants also demonstrated lower E:A ratios compared with healthy participants, as described previously. Changes in the E:A ratio reflect elevated filling pressures, which in turn reduce the filling velocity, reflecting early diastolic disease. However, transmitral Doppler patterns such as the E:A ratio are sensitive to preload and therefore display a nonlinear progression in diastolic disease ("pseudonormalization"). By comparison, assessment with tissue Doppler imaging is less load dependent and as such is a more linear and reliable measure of progressive diastolic impairment. Here, E 0 reflects the velocity of early myocardial relaxation as the mitral annulus ascends during early rapid LV filling. Thus, an E:E 0 ratio (taking lateral annular values) <8 is normal, and values >10 correlate with elevated LV end-diastolic pressures. 27 The primary aim of the study was to test the hypothesis that increases in small artery wall thickness and wall-to-lumen ratio are associated with impaired diastolic indices in patients with metabolic syndrome. In this regard, the major observation from this study was that lateral E:E 0 values significantly correlated with subcutaneous small artery wall-to-lumen ratio, even after adjustment for age and sex. The association of diastolic dysfunction with abnormal small artery remodeling was further strengthened by significant correlations between left atrial volume and both small artery wall thickness and the wall-to-lumen ratio. Left atrial dilatation is invariably present in heart failure, irrespective of ejection fraction, 28 and it is established that left atrial volume increases proportionally with the severity of diastolic dysfunction, independent of comorbid risks. 29 As such, left atrial volume is felt to be one of the most sensitive and specific measures to differentiate between HFpEF and hypertensive changes to the heart. 28 In contrast, there were no significant relationships between the endothelial-derived vasodilatory capacity of the artery and cardiac function. Our study is small and not powered to conclusively rule out relationships between small artery indices where no significance is seen. However, the lack of association between diastolic parameters and endothelial vasodilation is consistent with existing literature. 30 As a driver for progressive cardiovascular dysfunction in obesity, inflammation is undoubtedly key. 5 Specifically in regard to HFpEF, Paulus has recently proposed that obesityrelated inflammation and subsequent overproduction of reactive oxygen species limits local NO bioavailability within cardiomyocytes inducing dysfunction. 5 Cytokines such as TNF-a have been reported to disrupt NO bioavailability in obesity, 31 which led us to assess systemic inflammation by measuring circulating TNF and IL-6. Although no associations were identified between TNF-a or high-sensitivity C-reactive protein and any of the echo parameters, there was a significant inverse relationship observed between lateral E:E 0 and IL-6 (b=À0.868, P=0.03). IL-6 exhibits complex biology: In addition to inflammatory processes, IL-6 is widely recognized for its the role in the regulation of metabolic, regenerative, and neural processes. 32 Indeed, IL-6 is released by skeletal muscle and has well-described regenerative and anti-inflammatory activities, working to inhibit cytokines such as TNF-a. 33 Furthermore, IL-6 À/À mice develop late-onset obesity, 34 glucose intolerance, and insulin resistance. 35 Against this background, the inverse relationship between E: E 0 and IL-6 may provide insights into the functional pleiotropy of IL-6 and its role in anti-inflammatory processes in skeletal muscle. Taken in totality, the associations observed between left atrial volume, the E:E 0 ratio, and the abnormal wall growth of small arteries in patients with metabolic syndrome support an association between small artery dysfunction and diastolic heart failure. The interpretation of our results within the hypothesis outlined above rests on an implied assumption of small artery pathology; namely, that processes occurring in subcutaneous small arteries mirror those in the myocardium. As such the findings are associative, but previous studies have shown that structural and functional changes that occur in subcutaneous small arteries in response to hypertension and diabetes mellitus 36 are mirrored in mesenteric, 37 coronary, 38 and cerebral 39 arteries. Also, abnormal structure of small retinal arteries in patients with type 1 diabetes mellitus predicts not only retinopathy 20 but also nephropathy, 40 suggestive of a generalized microvascular burden. Although we have presented correlation analyses in graphical form, our adjusted logistic regression models validly describe the association between small vessel morphology with respect to CSA, wall thickness, wall-to-lumen ratio, and endothelial function, with corresponding echo parameters. In the absence of follow-up on small artery morphology at baseline and incident changes in echo parameters over time, which is prohibitively challenging because of repeated invasive biopsies required, it would not be possible to imply causation or anything beyond an association. Although this might be considered a limitation in study design, direct interrogation of human arterial tissue samples provides mechanistic insights beyond that afforded by biomarker studies, where association is again an inherent limitation. Patients with preclinical diastolic dysfunction and diabetes mellitus have more than double the rates of progression to symptomatic heart failure and mortality compared with those without diabetes mellitus. 41 From a translational perspective, it is therefore important to examine the temporal link between development of risk factors, functional changes to small arteries, and myocardial dysfunction, to determine the sequence of events that ultimately lead to symptomatic heart failure and premature death in these patients. The data from this study suggest that manipulation of these molecular targets within small arteries may be relevant to the treatment of diastolic heart failure.
